Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06466005 · ClinicalTrials.gov registry record
UnityPhilly Response App for Overdose Reversal
A clinical trial, sponsored by Drexel University.
- Recruiting
- Registry status
- 450
- Enrollment target
NCT06466005: Recruiting study, sponsored by Drexel University.
NCT06466005 is a clinical trial that is actively recruiting participants, run by Drexel University. The registered enrollment target is 450 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06466005 is actively recruiting participants, sponsored by Drexel University.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to discover if an overdose prevention app (UnityPhilly) can encourage citizen responders to respond and prevent opioid overdoses using the UnityPhilly app. The main hypotheses to answer are: Hypothesis 1: UnityPhilly signal rates relative to EMS calls will increase over time. The primary outcome will be assessed as the total number of overdoses signaled by participants relative to all overdose-related EMS calls, per year. Hypothesis 2: The number of cases where a nearby UnityPhilly participant successfully reverses an overdose with naloxone will increase over time. The primary outcome will be assessed as the number of successful reversals relative to the total number of responder arrivals, per year. Participants will be supplied with the UnityPhilly app, training on how to use the app and respond to an opioid overdose using naloxone, and respond to follow up surveys about their experiences.
Primary Outcome
\# events signaled by participants vs. # all overdose-related EMS calls, per year
Interventions
- OTHER UnityPhilly app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2028-07 |
What NCT06466005 shows while recruiting
NCT06466005 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which UnityPhilly app is the first listed.
NCT06466005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06466005 about?
NCT06466005 is a clinical study titled "UnityPhilly Response App for Overdose Reversal". The goal of this clinical trial is to discover if an overdose prevention app (UnityPhilly) can encourage citizen responders to respond and prevent opioid overdoses using the UnityPhilly app. The main hypotheses to answer are: Hypothesis 1: UnityPhilly signal rates relative to EMS calls will increas...
What is the current status of trial NCT06466005?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2025-09-16. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06466005?
The interventions under investigation include: UnityPhilly app (OTHER).
Who is sponsoring clinical trial NCT06466005?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI